NeuroSense Reports Statistically Significant 18-Month Phase 2b Data Showing PrimeC Slows ALS Progression With Early Treatment Advantage
Author: Benzinga Newsdesk | September 02, 2025 08:42am
NeuroSense Therapeutics Ltd. today announced a new analysis of 18-month data from its Phase 2b PARADIGM study of PrimeC in ALS.
●
Statistically significant effect at 18 months (p=0.03) demonstrated by NfL-adjusted MMRM analysis
●
This was reflected in 28% relative difference in ALS Functional Rating Scale-Revised (ALSFRS-R) decline favoring patients who received PrimeC from the beginning of the study versus patients who started the trial with placebo and received PrimeC after six months
●
Data underscore the clinical importance of initiating PrimeC early in disease progression
The analysis, adjusted for baseline neurofilament light (NfL, a biomarker of disease aggressiveness), confirms that the observed benefit is consistent after accounting for patient variability.
These results show a clear, statistically validated separation in functional outcomes, reinforcing PrimeC's potential as a disease-modifying therapy for ALS.
